[go: up one dir, main page]

PE20142282A1 - Nuevos derivados de aril-quinolina - Google Patents

Nuevos derivados de aril-quinolina

Info

Publication number
PE20142282A1
PE20142282A1 PE2014000640A PE2014000640A PE20142282A1 PE 20142282 A1 PE20142282 A1 PE 20142282A1 PE 2014000640 A PE2014000640 A PE 2014000640A PE 2014000640 A PE2014000640 A PE 2014000640A PE 20142282 A1 PE20142282 A1 PE 20142282A1
Authority
PE
Peru
Prior art keywords
phenyl
quinoline
carboxyl acid
quinoline derivatives
nitro
Prior art date
Application number
PE2014000640A
Other languages
English (en)
Inventor
Simona M Ceccarelli
Aurelia Conte
Holger Kuehne
Bernd Kuhn
Werner Neidhart
Sander Ulrike Obst
Markus Rudolph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20142282A1 publication Critical patent/PE20142282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE R1 ES ALQUILO, HALOALQUILO, CICLOALQUILO, ENTRE OTROS; R2 ES H, HALOGENO, ALQUILO, ENTRE OTROS; R3 ES H, HALOALCOXI, AMINO, ENTRE OTROS; R4 ES NITRO, CIANO, AMINO, ENTRE OTROS; R5 ES HIDROGENO, CICLOALCOXI, AMINOALQUILO, ENTRE OTROS; R6 ES FENILO, FENILO SUSTITUIDO, PIRIDINILO, ENTRE OTROS, R7 ES -COOH, TETRAZOL-5-ILO, ENTRE OTROS; n ES 0-1. SON COMPUESTOS PREFERIDOS ACIDO 6-CLORO-2-CICLOPROPIL-4-FENIL-QUINOLINA-3-CARBOXILICO; ACIDO 6-CLORO-2-ISOPROPIL-4-FENIL-QUINOLINA-3-CARBOXILICO, ACIDO 2-ETOXI-6-NITRO-4-FENIL-QUINOLINA-3-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE LA DIABETES TIPO 2.
PE2014000640A 2011-11-04 2012-10-29 Nuevos derivados de aril-quinolina PE20142282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187967 2011-11-04

Publications (1)

Publication Number Publication Date
PE20142282A1 true PE20142282A1 (es) 2015-01-08

Family

ID=47115939

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000640A PE20142282A1 (es) 2011-11-04 2012-10-29 Nuevos derivados de aril-quinolina

Country Status (22)

Country Link
US (2) US9199938B2 (es)
EP (1) EP2773619B1 (es)
JP (1) JP6170060B2 (es)
KR (1) KR20140088194A (es)
CN (1) CN103906735B (es)
AR (1) AR088625A1 (es)
AU (1) AU2012331289B2 (es)
BR (1) BR112014010644A2 (es)
CA (1) CA2849945A1 (es)
CL (1) CL2014001060A1 (es)
CO (1) CO6930359A2 (es)
CR (1) CR20140135A (es)
EA (1) EA201490846A1 (es)
ES (1) ES2609773T3 (es)
IL (1) IL231950B (es)
MX (1) MX343893B (es)
MY (1) MY169267A (es)
PE (1) PE20142282A1 (es)
PH (1) PH12014500814A1 (es)
SG (1) SG11201401937YA (es)
TW (1) TWI616437B (es)
WO (1) WO2013064465A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906735B (zh) 2011-11-04 2016-12-07 霍夫曼-拉罗奇有限公司 新芳基-喹啉衍生物
CA2873295A1 (en) * 2012-08-24 2014-02-27 F. Hoffmann-La Roche Ag New bicyclicpyridine derivatives
CN105294648B (zh) * 2015-11-30 2017-11-28 山东罗欣药业集团股份有限公司 一种西他沙星的制备方法
WO2017184547A1 (en) * 2016-04-18 2017-10-26 New York University Quinoline compounds as modulators of rage activity and uses thereof
EP3246028A1 (en) * 2016-05-18 2017-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline compounds for increasing insuline release
JP7139323B2 (ja) 2016-11-01 2022-09-20 エフ．ホフマン－ラ ロシュ アーゲー Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
WO2018165120A1 (en) * 2017-03-06 2018-09-13 Gemphire Therapeutics Inc. Effect of carboxyalkylethers on obesity symptoms and lipodystropy
CN107311847B (zh) * 2017-07-12 2020-11-10 安徽省诚联医药科技有限公司 5-溴-2-氯-4′-乙氧基二苯甲烷的制备方法
CN109280028B (zh) * 2017-07-19 2022-03-25 上海医药工业研究院 喹啉类化合物及其在dpp-4酶抑制剂的应用
CA3099610A1 (en) 2018-05-09 2019-11-14 Bayer Animal Health Gmbh New quinoline derivatives
WO2020227331A1 (en) * 2019-05-06 2020-11-12 Inspira, LLC Chemical entities, pharmaceutical formulations, and methods for treating fibrosis
BR112022026550A2 (pt) 2020-06-27 2023-01-17 Crescenta Biosciences Composição de compostos que modulam o metabolismo celular e métodos de uso
US20220313681A1 (en) * 2020-07-06 2022-10-06 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseases
CN113277978B (zh) * 2021-06-02 2022-06-03 河南师范大学 一种2，4-双取代喹啉类化合物的制备方法
KR20240088970A (ko) 2021-09-24 2024-06-20 제논 파마슈티칼스 인크. 소듐 채널 활성화제로서 피리딘 유도체 및 이의 용도
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds
CN116693456A (zh) * 2022-02-28 2023-09-05 复旦大学 异喹啉酮类化合物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
TW205037B (es) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
US5371227A (en) 1991-10-28 1994-12-06 Synthelabo Quinoline derivatives, process for their preparation, and their therapeutic applications
JP3724818B2 (ja) * 1992-09-04 2005-12-07 武田薬品工業株式会社 縮合複素環化合物、その製造法および剤
EP0585913B1 (en) * 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
JPH0769890A (ja) * 1993-06-29 1995-03-14 Takeda Chem Ind Ltd キノリンまたはキナゾリン誘導体を含んでなる医薬組成物
JPH08225531A (ja) * 1994-03-08 1996-09-03 Takeda Chem Ind Ltd キノリンまたはキナゾリン誘導体を含んでなる医薬およびそれに用いる新規誘導体
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AU2003265382A1 (en) * 2002-08-23 2004-03-11 Pharmacia & Upjohn Company Llc Antibacterial benzoic acid derivatives
AU2003284704A1 (en) * 2002-11-29 2004-06-23 C And C Research Laboratories Substituted 1h-pyridine-2-one derivatives
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
EP1660087A2 (en) * 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2009040290A1 (en) 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5ht5a receptor antagonists
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
GB0818365D0 (en) 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinoline compounds
WO2010056631A1 (en) * 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
WO2010056865A1 (en) * 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
CN103906735B (zh) 2011-11-04 2016-12-07 霍夫曼-拉罗奇有限公司 新芳基-喹啉衍生物
BR112014010133B1 (pt) 2011-11-04 2019-12-24 Syngenta Participations Ag composto pesticida, composição farmacêutica que compreende o composto pesticida e material de propagação de plantas tratado
US20130116263A1 (en) 2011-11-04 2013-05-09 Afraxis, Inc. Pak inhibitors for the treatment of cell proliferative disorders

Also Published As

Publication number Publication date
MY169267A (en) 2019-03-20
JP2014532681A (ja) 2014-12-08
MX343893B (es) 2016-11-28
US20160060270A1 (en) 2016-03-03
PH12014500814A1 (en) 2014-05-19
IL231950B (en) 2018-02-28
TW201326130A (zh) 2013-07-01
JP6170060B2 (ja) 2017-07-26
MX2014005373A (es) 2014-07-30
CA2849945A1 (en) 2013-05-10
AR088625A1 (es) 2014-06-25
AU2012331289B2 (en) 2017-07-13
EA201490846A1 (ru) 2014-07-30
WO2013064465A1 (en) 2013-05-10
CO6930359A2 (es) 2014-04-28
EP2773619A1 (en) 2014-09-10
NZ720278A (en) 2017-08-25
CR20140135A (es) 2014-06-19
US9199938B2 (en) 2015-12-01
TWI616437B (zh) 2018-03-01
CN103906735B (zh) 2016-12-07
NZ622717A (en) 2016-06-24
ES2609773T3 (es) 2017-04-24
AU2012331289A1 (en) 2014-04-10
US20130116234A1 (en) 2013-05-09
CN103906735A (zh) 2014-07-02
BR112014010644A2 (pt) 2017-04-25
CL2014001060A1 (es) 2014-11-07
SG11201401937YA (en) 2014-05-29
US9809599B2 (en) 2017-11-07
EP2773619B1 (en) 2016-11-16
KR20140088194A (ko) 2014-07-09

Similar Documents

Publication Publication Date Title
PE20142282A1 (es) Nuevos derivados de aril-quinolina
PE20141996A1 (es) Compuestos con actividad nematicida
PE20141726A1 (es) Heterociclilaminas como inhibidores de pi 3k
PE20140968A1 (es) Derivados de benzamida sustituida
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20130155A1 (es) Derivados de ariletinilo
PE20141042A1 (es) Nuevos derivados biciclicos de dihidroquinolina-2-ona
AR083169A1 (es) Compuestos para tratar enfermedades neurodegenerativas
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20091446A1 (es) Derivados de isoxazolo-piridazina
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
PE20151538A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
EA201170096A1 (ru) Замещенные производные пиримидона
AR073136A1 (es) Compuestos de pirrol

Legal Events

Date Code Title Description
FC Refusal